Drug Profile
BCI 632
Alternative Names: BCI-632Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Taisho Pharmaceutical
- Developer BrainCells
- Class Antidepressants
- Mechanism of Action Metabotropic glutamate receptor 2 antagonists; Metabotropic glutamate receptor 3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Major depressive disorder
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Major depressive disorder(In volunteers) in USA
- 02 Mar 2012 Phase-I clinical trials in volunteers in USA (unspecified route)
- 03 Nov 2010 Preclinical trials in Major depressive disorder in USA (unspecified route)